Drugs / PCS12852
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05270460 | Mar → Sep 2022 | gastroparesis | Processa Pharmaceuticals | Completed | Met primary |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2023-04-28 | Processa Pharmaceuticals | Results Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting processapharmaceuticals.com ↗
Sian Bigora, Pharm.D., Processa Pharmaceuticals’ Chief Development and Regulatory Officer, will present the Phase 2a results on the improvement in symptom scores and gastric emptying rate in gastroparesis patients treated with PCS12852. |
| 2022-12-14 | Processa Pharmaceuticals | Results Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial processapharmaceuticals.com ↗
A 0.5 mg daily dose of PCS12852 administered over 28 days in gastroparesis patients successfully improved gastroparesis symptoms in a clinically meaningful way as defined by greater than a 0.5 reduction in the ANMS GCSI-DD score compared to baseline. |
| 2022-11-08 | Processa Pharmaceuticals | Results Processa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update processapharmaceuticals.com ↗
We are delighted to report our push to enroll patients in PCS12852 (Gastroparesis) and PCS6422 (Next Generation Capecitabine) has helped us get critical data and report successful preliminary results in both trials. |
| 2022-11-08 | Processa Pharmaceuticals | Results PCS12852 Improves Gastric Emptying in Gastroparesis Patients processapharmaceuticals.com ↗
In a Phase 2A Proof-of-Concept trial, the Gastric Emptying Breath Test (GEBT) results demonstrated statistical improvement in gastric emptying in gastroparesis patients receiving 0.5 mg of PCS12852 (6 patients) as compared to placebo (8 patients) at a p < 0.10 level. |
| 2021-10-12 | Processa Pharmaceuticals | Regulatory Processa Pharmaceuticals Cleared by FDA to Proceed with Phase 2a Trial for the Treatment of Gastroparesis processapharmaceuticals.com ↗ |
All press releases naming this drug 6 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PCS12852 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05270460 ↗ |
| Route | Oral | “PCS12852 oral tablet administered once daily” NCT05270460 ↗ |